Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI
Shruti Gupta,Clara Garcia-Carro,Jason M Prosek,Ilya Glezerman,Sandra M Herrmann,Pablo Garcia,Ala Abudayyeh,Nuttha Lumlertgul,A Bilal Malik,Sebastian Loew,Pazit Beckerman,Amanda D Renaghan,Christopher A Carlos,Arash Rashidi,Zain Mithani,Priya Deshpande,Sunil Rangarajan,Chintan V Shah,Sophie De Seigneux,Luca Campedel,Abhijat Kitchlu,Daniel Sanghoon Shin,Gaia Coppock,David I Ortiz-Melo,Ben Sprangers,Vikram Aggarwal,Karolina Benesova,Rimda Wanchoo,Naoka Murakami,Frank B Cortazar,Kerry L Reynolds,Meghan E Sise,Maria Jose Soler,David E Leaf,ICPi-AKI Consortium Investigators,Joe-Elie Salem,Corinne Isnard Bagnis,Harkarandeep Singh,Shveta S Motwani,Maria C Tio,Suraj S Mothi,Umut Selamet,Kai M Schmidt-Ott,Weiting Chang,Kenar D Jhaveri,Yuriy Khanin,Jamie S Hirsch,Vipulbhai Sakhiya,Daniel Stalbow,Sylvia Wu,Marlies Ostermann,Nina Seylanova,Armando Cennamo,Anne Rigg,Nisha Shaunak,Zoe A Kibbelaar,Harish S Seethapathy,Meghan Lee,Ian A Strohbhen,Busra Isik,Ilya G Glezerman,Sunandana Chandra,Sethu M Madhavan,Dwight H Owen,Marium Husain,Sharon Mini,Shuchi Anand,Aydin Kaghazchi,Grace Cherry,Raymond K Hsu,Andrey Kisel,Sheru K Kansal,Nicole Albert,Katherine Carter,Vicki Donley,Tricia Young,Heather Cigoi,Thibaud Koessler,Els Wauters Ben Sprangers,Mark Eijgelsheim,Javier A Pagan,Jonathan J Hogan,Omar Mamlouk,Jamie S Lin,Valda Page,Samuel Ap Short,Elizabeth M Gaughan,Clara García-Carro,Sheila Bermejo,Enriqueta Felip,Eva Muñoz-Couselo,Maria Josep Carreras
DOI: https://doi.org/10.1136/jitc-2022-005646
Abstract:Background: Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adverse effects and may decrease progression-free survival among patients treated with ICPis. We sought to determine whether a shorter duration of corticosteroids was equally efficacious and safe as compared with a longer duration. Methods: We used data from an international multicenter cohort study of patients diagnosed with ICPi-AKI from 29 centers across nine countries. We examined whether a shorter duration of corticosteroids (28 days or less) was associated with a higher rate of recurrent ICPi-AKI or death within 30 days following completion of corticosteroid treatment as compared with a longer duration (29-84 days). Results: Of 165 patients treated with corticosteroids, 56 (34%) received a shorter duration of treatment and 109 (66%) received a longer duration. Patients in the shorter versus longer duration groups were similar with respect to baseline and ICPi-AKI characteristics. Five of 56 patients (8.9%) in the shorter duration group and 12 of 109 (11%) in the longer duration group developed recurrent ICPi-AKI or died (p=0.90). Nadir serum creatinine in the first 14, 28, and 90 days following completion of corticosteroid treatment was similar between groups (p=0.40, p=0.56, and p=0.89, respectively). Conclusion: A shorter duration of corticosteroids (28 days or less) may be safe for patients with ICPi-AKI. However, the findings may be susceptible to unmeasured confounding and further research from randomized clinical trials is needed.